Is Tofacitinib produced in China?

Tofacitinib (Tofacitinib), developed and produced by Pfizer Inc. The original drug was first approved by the State Food and Drug Administration in March 2017. Common specifications include tablets, sustained-release tablets, and oral solution preparations. Tablets are marketed in China under the trade name Shangjie. In addition to the original drug, it is currently available in Qilu, Kelun, Yangzijiang, etc. 16 Domestic drugs have been approved for marketing, and their drug ingredients are basically the same as those of the original drugs.

Tofacitinib is indicated for the treatment of moderate to severe rheumatoid arthritis (RA), psoriatic arthritis (PA), ulcerative colitis (UC), and polyarticular juvenile idiopathic arthritis (pcJIA), It is a second-generation selective Janus kinase (JAK) inhibitor targeting the JAK1 enzyme. Janus kinase is a phosphotransferase, and cytokine receptors participate in activating its enzyme function. Janus kinase inhibitors represent new strategies for treating immune and inflammatory diseases. Tofacitinib is an oral inhibitor of Janus kinase that targets synthetic small molecules.

Tofacitinib entered the scope of Class B medical insurance after being launched in China. The common specification is tofacitinib citrate tablets. The price paid by medical insurance is relatively cheap, butthe reimbursement ratio is different in different regions, and the price after reimbursement will be different. Overseas, there are also generic drugs of tofacitinib produced in other countries. The price of each box produced by a Bangladeshi pharmaceutical factory is around 300 yuan (the price may fluctuate due to the exchange rate). The ingredients of domestic original drugs and foreign generic drugs are basically the same, and the prices of different specifications will be different.